BMJ 2014 Cochrane Review [1] What They Did: Systematic review of randomized placebo controlled trials on adults and children with confirmed or suspected exposure to influenza Outcomes (Divided into Treatment and Prophylaxis Outcomes): Primary Outcomes in Treatment Studies: Time to first alleviation of symptoms Influenza outcomes Complications Admissions to hospital Adverse events Secondary Outcomes in Treatment Studies: Symptom relapse after finishing treatment Drug resistance Viral excretion Mortality Primary Outcomes in Prophylaxis Studies: Influenza (Symptomatic and asymptomatic, always with laboratory confirmation) Influenza-like illness Admission to hospital Complications Interruption of transmission (i.e Viral spread from index cases and prevention of onset of influenza in contacts) Harms Secondary Outcomes for Prophylaxis Studies: Drug resistance Viral excretion Mortality Inclusion: Randomized controlled trials evaluating the effects of oseltamivir for treatment, prophylaxis, and post-exposure prophylaxis of influenza Exclusion: Open label studies and those not involving naturally occurring influenza Also excluded patients who were immunocompromised (i.e

Ileal protein carbonyls, as marker of protein oxidation, were measured by an ELISA according to the method of Buss et al
Only 10-20% of oral glutathione actually gets absorbed
Unlike phentermine, semaglutide is approved for long-term use
[PubMed] Videla LA, Rodrigo R, Orellana M, Fernandez V, Tapia G, Quiones L, Varela N, Contreras J, Lazarte R, Csendes A, Rojas J, Maluenda F, Burdiles P, Diaz JC, Smok G, Thielemann L, Poniachik J (2004) Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients
The semaglutide sodium salt dissociates in solution, meaning that the actual therapeutic molecule present in the final compounded product is the same semaglutide peptide found in brand-name products